Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reduced their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Price Performance

ESPR opened at $2.41 on Tuesday. The company has a fifty day moving average price of $1.97 and a 200-day moving average price of $2.14. The firm has a market capitalization of $474.87 million, a P/E ratio of -3.63 and a beta of 0.96. Esperion Therapeutics has a one year low of $1.15 and a one year high of $3.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Wasatch Advisors LP grew its position in Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares in the last quarter. Bellevue Group AG grew its position in Esperion Therapeutics by 136.5% in the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares in the last quarter. Vanguard Group Inc. grew its position in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after acquiring an additional 3,688,796 shares in the last quarter. Marshall Wace LLP grew its position in Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after acquiring an additional 2,087,635 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after acquiring an additional 555,382 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.